Cancer cell antigen (null)

Cancer cell antigens (often known as tumor antigens or tumor cell antigens) are molecules expressed by cancer cells that can be recognized by the immune system. They are broadly divided into two categories: tumor-specific antigens (TSAs), which are unique to cancer cells, and tumor-associated antigens (TAAs), which are overexpressed in cancer cells but can also be found at lower levels in some normal tissues[1][2][3][5]. TSAs typically arise from genetic mutations (neoantigens, mutated proteins, viral antigens), while TAAs may include overexpressed self-proteins, differentiation antigens, and cancer-testis antigens[1][2][3]. These antigens underpin modern immunotherapy strategies such as cancer vaccines and adoptive T-cell therapy, with therapeutic challenges including antigen heterogeneity, cross-reactivity with normal tissues, and immune escape[1][2][3][5]. Because “cancer cell antigens” is an umbrella term encompassing many molecules rather than a single gene or protein, it is not itself a canonical molecular target but refers to a broad class of immunologically actionable targets. The term “Cancer cell antigens” is imprecise as a target, referring to a heterogeneous group of molecular structures rather than a single molecule. For structured programming or drug development, a specific antigen (e.g., HER2, MAGE-A3, NY-ESO-1) should be specified for more precise information[3][5].

Other names

Tumor antigenTumor cell antigenTumor-associated antigen (TAA)Tumor-specific antigen (TSA)Cancer-testis antigen (CTA)NeoantigenOncofetal antigen

Immune-mediated killing via T-cell recognition of antigen; Antibody-dependent cellular cytotoxicity (ADCC); Direct killing/blocking by monoclonal antibodies; Vaccine-induced immune activation.